Panacea Infarm has announced a price reduction for Merovir for countries with a low standard of living (Russia, CIS, some European countries, South America, African countries).
Hepatitis B is recognized as a global epidemic due to its high prevalence and a major risk of being affected by a virus. Until recently, the disease was considered incurable.
Scientists got the clinical trials results of the drug FABI256 aimed to treat chronic viral hepatitis B and D.
The Australian company Panacea Infarm is a major player in the biopharmaceutical market engaged in the development of various drugs. The company has announced its plans to transfer the right to manufacture generic of its drug no earlier than one year from now.
Hepatitis B is the only virus coping with the existing vaccine against it, still continuing to kill millions of people worldwide. Today Hepatitis B drugs represent a separate pharmaceutical market.
Hepatitis B incidence statistics are depressing, to put it mildly. According to the results of a large-scale study published in The Lancet Gastroenterology & Hepatology, only 1 out of 20 patients with the virus among the 300 million infected receives the required treatment.
Statistics show that more than 1 million people worldwide dies from different hepatitis B effects. According to Rospotrebnadzor (Federal Service for Consumer Rights Protection and Human Welfare in Russian Federation), in 2017 over 14,000 cases of chronic hepatitis B were registered in Russia, 1.3 thousand people suffers from an acute condition of this disease. All that the contemporary pharmaceutical market can offer such patients today is medicines suppressing the virus but not destroying it.
The company Panacea Infarm continues to work on a clinical trial for patients suffering from chronic viral hepatitis B with the delta agent.
Hepatitis B is a worldwide public health problem. This potentially life-threatening infection affects a liver. The complications may result in the development of cirrhosis and cancer.